Boothbay Fund Management’s Sage Therapeutics SAGE Stock Holding History

Boothbay Fund Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-473,500	Closed	-$5.14M	–	1890
2024 Q2	$5.14M	Buy	+473,500	New	+$6.07M	0.12%	218
2022 Q3	–	Sell	-30,700	Closed	-$992K	–	2559
2022 Q2	$992K	Hold	30,700	–	–	0.03%	812
2022 Q1	$1.02M	Buy	+30,700	New	+$1.15M	0.02%	890
2021 Q3	–	Sell	-28,700	Closed	-$1.63M	–	2149
2021 Q2	$1.63M	Buy	28,700 +28,580	+23,817%	+$2.02M	0.05%	472
2021 Q1	$898K	Buy	120 +44	+58%	+$3.61K	0.03%	653
2020 Q4	$657K	Buy	76 +27	+55%	+$1.99K	0.02%	649
2020 Q3	$299K	Sell	49 -103	-68%	-$5.22K	0.02%	805
2020 Q2	$632K	Buy	152 +18	+13%	+$653	0.04%	520
2020 Q1	$385K	Buy	+134	New	+$7.76K	0.03%	508
2019 Q4	–	Sell	-192	Closed	-$2.69M	–	969
2019 Q3	$2.69M	Buy	+192	New	+$32.1K	0.25%	97
2018 Q1	–	Sell	-21	Closed	-$346K	–	847
2017 Q4	$346K	Sell	21 -228	-92%	-$22.1K	0.05%	382
2017 Q3	$1.55M	Buy	+249	New	+$19.6K	0.26%	97

Other funds holding SAGE

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Boothbay Fund Management's SAGE Position: Q2 2025 in Review

Boothbay Fund Management sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 1,384,465 shares — an estimated $11M sold.

Boothbay Fund Management first reported a position in SAGE in Q4 2017 and held it in 14 quarters. The position peaked at $11M in Q1 2025. 191 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

Boothbay Fund Management reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
Boothbay Fund Management sold 1,384,465 Sage Therapeutics shares in Q2 2025, an estimated $11M.
Boothbay Fund Management first reported a position in Sage Therapeutics in Q4 2017 and held it in 14 quarters.
Boothbay Fund Management's Sage Therapeutics position peaked at $11M in Q1 2025.
191 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.